Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

A. Cortellini, K. Cannita, M. Tiseo, D.L. Cortinovis, J.G.J.V. Aerts, C. Baldessari, R. Giusti, M.G. Ferrara, E. D'Argento, F. Grossi, A. Guida, R. Berardi, A. Morabito, C. Genova, L. Antonuzzo, F. Mazzoni, A. De Toma, D. Signorelli, A. Gelibter, G. TargatoF. Rastelli, R. Chiari, D. Rocco, S. Gori, M. De Tursi, G. Mansueto, F. Zoratto, M. Filetti, S. Bracarda, F. Citarella, R. Marco, L. Cantini, O. Nigro, S. Buti, G. Minuti, L. Landi, S. Ricciardi, M.R. Migliorino, S. Natalizio, C. Simona, M. De Filippis, G. Metro, V. Adamo, A. Russo, G.P. Spinelli, M. Di Maio, G.L. Banna, A. Friedlaender, A. Addeo, D.J. Pinato, C. Ficorella, G. Porzio

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)24-35
Number of pages12
JournalEuropean Journal of Cancer
Volume148
DOIs
Publication statusPublished - 2021

Keywords

  • Immunotherapy
  • Non-small cell lung cancer
  • PD-L1
  • Pembrolizumab
  • Performance status
  • Post-progression
  • Radiation therapy
  • Radiotherapy
  • corticosteroid
  • pembrolizumab
  • programmed death 1 ligand 1
  • adult
  • aged
  • Article
  • bone metastasis
  • cancer chemotherapy
  • cancer mortality
  • cancer patient
  • cancer radiotherapy
  • central nervous system metastasis
  • clinical outcome
  • cohort analysis
  • comparative study
  • descriptive research
  • doublet chemotherapy
  • drug substitution
  • drug withdrawal
  • ECOG Performance Status
  • female
  • follow up
  • human
  • liver metastasis
  • lung carcinogenesis
  • major clinical study
  • male
  • multicenter study
  • non small cell lung cancer
  • overall survival
  • priority journal
  • protein expression
  • sex difference
  • single drug dose

Cite this